Capital World Investors’s Myriad Genetics MYGN Stock Holding History

Capital World Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-592,800	Closed	-$12.2M	–	503
2016 Q3	$12.2M	Sell	592,800 -509,921	-46%	-$12.9M	﹤0.01%	434
2016 Q2	$33.7M	Sell	1,102,721 -200,000	-15%	-$6.95M	0.01%	363
2016 Q1	$48.8M	Sell	1,302,721 -5,357,317	-80%	-$202M	0.01%	331
2015 Q4	$287M	Sell	6,660,038 -2,148,147	-24%	-$90.8M	0.08%	201
2015 Q3	$330M	Sell	8,808,185 -131,815	-1%	-$4.68M	0.1%	187
2015 Q2	$304M	Hold	8,940,000	–	–	0.08%	208
2015 Q1	$316M	Hold	8,940,000	–	–	0.09%	199
2014 Q4	$304M	Buy	8,940,000 +1,284,885	+17%	+$45.6M	0.08%	202
2014 Q3	$295M	Buy	7,655,115 +2,360,036	+45%	+$88.1M	0.08%	200
2014 Q2	$206M	Buy	5,295,079 +2,100,079	+66%	+$78.1M	0.06%	237
2014 Q1	$109M	Buy	+3,195,000	New	+$99M	0.03%	283

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Capital World Investors's MYGN Position: Q4 2016 in Review

Capital World Investors sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 592,800 shares — an estimated $12.2M sold.

Capital World Investors first reported a position in MYGN in Q1 2014 and held it in 11 quarters. The position peaked at $330M in Q3 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

Capital World Investors reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
Capital World Investors sold 592,800 Myriad Genetics shares in Q4 2016, an estimated $12.2M.
Capital World Investors first reported a position in Myriad Genetics in Q1 2014 and held it in 11 quarters.
Capital World Investors's Myriad Genetics position peaked at $330M in Q3 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Capital World Investors's 13F filing for Q4 2016, filed 15 Feb 2017.